202 related articles for article (PubMed ID: 30732487)
1. Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.
Zhao J; Jiang K; Li Q; Zhang Y; Cheng Y; Lin Z; Xuan J
J Med Econ; 2019 May; 22(5):439-446. PubMed ID: 30732487
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China.
Lin Z; Xuan J
Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):549-557. PubMed ID: 32757968
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.
Ascher-Svanum H; Furiak NM; Lawson AH; Klein TM; Smolen LJ; Conley RR; Culler SD
J Med Econ; 2012; 15(3):531-47. PubMed ID: 22304338
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
Davies A; Vardeva K; Loze JY; L'italien GJ; Sennfalt K; Baardewijk Mv
Curr Med Res Opin; 2008 Nov; 24(11):3275-85. PubMed ID: 18947458
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness and Price of Aripiprazole for Schizophrenia in the Brazilian Public Health System.
Soares Santos A; de Souza Noronha KVM; Viegas Andrade M; Mariano Ruas C
J Ment Health Policy Econ; 2020 Mar; 23(1):27-37. PubMed ID: 32458815
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Encephale; 2017 Aug; 43(4):311-320. PubMed ID: 27623123
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
9. Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China.
Yi ZM; Men P; Qu S; Li C; Yu X; Zhai S
Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):313-320. PubMed ID: 32293194
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
[TBL] [Abstract][Full Text] [Related]
11. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia.
Rajagopalan K; Trueman D; Crowe L; Squirrell D; Loebel A
Pharmacoeconomics; 2016 Jul; 34(7):709-21. PubMed ID: 27067724
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.
Knapp M; Windmeijer F; Brown J; Kontodimas S; Tzivelekis S; Haro JM; Ratcliffe M; Hong J; Novick D;
Pharmacoeconomics; 2008; 26(4):341-58. PubMed ID: 18370568
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.
Furiak NM; Ascher-Svanum H; Klein RW; Smolen LJ; Lawson AH; Montgomery W; Conley RR
Curr Med Res Opin; 2011 Apr; 27(4):713-30. PubMed ID: 21265593
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
Zeidler J; Mahlich J; Greiner W; Heres S
Appl Health Econ Health Policy; 2013 Oct; 11(5):509-21. PubMed ID: 23975630
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.
Edwards NC; Rupnow MF; Pashos CL; Botteman MF; Diamond RJ
Pharmacoeconomics; 2005; 23(3):299-314. PubMed ID: 15836010
[TBL] [Abstract][Full Text] [Related]
16. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.
Kasteng F; Eriksson J; Sennfält K; Lindgren P
Acta Psychiatr Scand; 2011 Sep; 124(3):214-25. PubMed ID: 21609324
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China.
Liu J; Cao L; Wu J
Front Public Health; 2022; 10():987408. PubMed ID: 36187655
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of paliperidone extended release in Spain.
Treur M; Baca E; Bobes J; Cañas F; Salvador L; Gonzalez B; Heeg B
J Med Econ; 2012; 15 Suppl 1():26-34. PubMed ID: 23016569
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia.
Ascher-Svanum H; Stensland MD; Peng X; Faries DE; Stauffer VL; Osuntokun OO; Kane JM
Curr Med Res Opin; 2011 Jan; 27(1):115-22. PubMed ID: 21110749
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
Einarson TR; Bereza BG; Tedouri F; Van Impe K; Denee TR; Dries PJT
J Med Econ; 2017 Nov; 20(11):1187-1199. PubMed ID: 28762843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]